Succinobucol (BioDeep_00000184008)
human metabolite blood metabolite
代谢物信息卡片
4-[2,6-Di-tert-butyl-4-({2-[(3,5-di-tert-butyl-4-hydroxyphenyl)sulphanyl]propan-2-yl}sulphanyl)phenoxy]-4-oxobutanoic acid
化学式: C35H52O5S2 (616.3255982000001)
中文名称: 琥珀丁醇
谱图信息:
最多检出来源 Homo sapiens(blood) 50%
分子结构信息
SMILES: CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)OC(=O)CCC(=O)O)C(C)(C)C
InChI: InChI=1S/C35H52O5S2/c1-31(2,3)23-17-21(18-24(29(23)39)32(4,5)6)41-35(13,14)42-22-19-25(33(7,8)9)30(26(20-22)34(10,11)12)40-28(38)16-15-27(36)37/h17-20,39H,15-16H2,1-14H3,(H,36,37)
描述信息
C26170 - Protective Agent > C275 - Antioxidant
同义名列表
5 个代谢物同义名
4-[2,6-Di-tert-butyl-4-({2-[(3,5-di-tert-butyl-4-hydroxyphenyl)sulphanyl]propan-2-yl}sulphanyl)phenoxy]-4-oxobutanoic acid; 4-[2,6-di-tert-butyl-4-({2-[(3,5-di-tert-butyl-4-hydroxyphenyl)sulfanyl]propan-2-yl}sulfanyl)phenoxy]-4-oxobutanoic acid; 4-[2,6-Di-tert-butyl-4-({2-[(3,5-di-tert-butyl-4-hydroxyphenyl)sulphanyl]propan-2-yl}sulphanyl)phenoxy]-4-oxobutanoate; 4-[2,6-Di-tert-butyl-4-({2-[(3,5-di-tert-butyl-4-hydroxyphenyl)sulfanyl]propan-2-yl}sulfanyl)phenoxy]-4-oxobutanoate; Succinobucol
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:177810
- PubChem: 216325
- HMDB: HMDB0258543
- DrugBank: DB05399
- ChEMBL: CHEMBL83626
- chemspider: 187514
- CAS: 216167-82-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Stephanie A Houston, Azizah Ugusman, Sukanya Gnanadesikan, Simon Kennedy. An investigation of the antiplatelet effects of succinobucol (AGI-1067).
Platelets.
2017 May; 28(3):295-300. doi:
10.1080/09537104.2016.1218456. [PMID: 27681689] - Renata Pietsch Ribeiro, Danúbia Bonfanti Santos, Dirleise Colle, Aline Aita Naime, Cinara Ludvig Gonçalves, Heloisa Ghizoni, Mariana Appel Hort, Marcelo Godoi, Paulo Fernando Dias, Antonio Luiz Braga, Marcelo Farina. Decreased forelimb ability in mice intracerebroventricularly injected with low dose 6-hydroxidopamine: A model on the dissociation of bradykinesia from hypokinesia.
Behavioural brain research.
2016 May; 305(?):30-6. doi:
10.1016/j.bbr.2016.02.023. [PMID: 26921691] - Dirleise Colle, Danúbia Bonfanti Santos, Juliana Montagna Hartwig, Marcelo Godoi, Daiane Fátima Engel, Andreza Fabro de Bem, Antonio L Braga, Marcelo Farina. Succinobucol, a Lipid-Lowering Drug, Protects Against 3-Nitropropionic Acid-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Cells via Upregulation of Glutathione Levels and Glutamate Cysteine Ligase Activity.
Molecular neurobiology.
2016 Mar; 53(2):1280-1295. doi:
10.1007/s12035-014-9086-x. [PMID: 25619973] - Eleni Ladopoulou, Alexios N Matralis, Angeliki P Kourounakis. New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
Journal of medicinal chemistry.
2013 Apr; 56(8):3330-8. doi:
10.1021/jm400101e. [PMID: 23581491] - Dirleise Colle, Danúbia B Santos, Juliana M Hartwig, Marcelo Godoi, Antonio L Braga, Marcelo Farina. Succinobucol versus probucol: higher efficiency of succinobucol in mitigating 3-NP-induced brain mitochondrial dysfunction and oxidative stress in vitro.
Mitochondrion.
2013 Mar; 13(2):125-33. doi:
10.1016/j.mito.2013.01.005. [PMID: 23333792] - Ondřej Jurček, Satu Ikonen, Lucie Buřičová, Martina Wimmerová, Zdeněk Wimmer, Pavel Drašar, Jan Horníček, Adéla Galandáková, Jitka Ulrichová, Erkki T Kolehmainen. Succinobucol's new coat--conjugation with steroids to alter its drug effect and bioavailability.
Molecules (Basel, Switzerland).
2011 Nov; 16(11):9404-20. doi:
10.3390/molecules16119404. [PMID: 22075571] - Young-Guk Ko, Byeong-Keuk Kim, Byoung Kwon Lee, Woong Chol Kang, Seung Hyuk Choi, Sang Wook Kim, Jong Ho Lee, Myoungsook Lee, Yasuhiro Honda, Peter J Fitzerald, Won-Heum Shim. Study design and rationale of 'Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)' study: a double-blind randomised controlled multicenter clinical trial.
Trials.
2011 Jan; 12(?):10. doi:
10.1186/1745-6215-12-10. [PMID: 21226953] - Tong Liu, Guangping Li. Probucol and succinobucol in atrial fibrillation: pros and cons.
International journal of cardiology.
2010 Oct; 144(2):295-6. doi:
10.1016/j.ijcard.2009.02.026. [PMID: 19278740] - Christos Paras, M Mahmood Hussain, Robert S Rosenson. Emerging drugs for hyperlipidemia.
Expert opinion on emerging drugs.
2010 Sep; 15(3):433-51. doi:
10.1517/14728214.2010.481282. [PMID: 20423271] - William S Crim, Runpei Wu, Jeffrey D Carter, Banumathi K Cole, Anthony P Trace, Raghavendra G Mirmira, Charles Kunsch, Jerry L Nadler, Craig S Nunemaker. AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets.
Molecular and cellular endocrinology.
2010 Jul; 323(2):246-55. doi:
10.1016/j.mce.2010.02.041. [PMID: 20211684] - Ben J Wu, Robyn G Midwinter, Carlos Cassano, Konstanze Beck, Yutang Wang, Dechaboon Changsiri, Jennifer R Gamble, Roland Stocker. Heme oxygenase-1 increases endothelial progenitor cells.
Arteriosclerosis, thrombosis, and vascular biology.
2009 Oct; 29(10):1537-42. doi:
10.1161/atvbaha.109.184713. [PMID: 19542024] - Victor Serebruany, Alex Malinin, Fei-Hua Qiu, X-C Xu, Charles Kunsch, Robert Scott. Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy.
Journal of thrombosis and thrombolysis.
2009 May; 27(4):438-46. doi:
10.1007/s11239-008-0233-y. [PMID: 18521540] - Jean-Claude Tardif, Jean Grégoire, Philippe L L'Allier, Reda Ibrahim, Todd J Anderson, François Reeves, Lawrence M Title, Erick Schampaert, Michel LeMay, Jacques Lespérance, Rob Scott, Marie-Claude Guertin, Marie-Luise Brennan, Stanley L Hazen, Olivier F Bertrand. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial.
Atherosclerosis.
2008 Mar; 197(1):480-6. doi:
10.1016/j.atherosclerosis.2006.11.039. [PMID: 17214993] - Michael H Davidson, Joseph Smith, Robert Scott, Robert Small, Jasmine Choi, Brian Y Ishida, John P Kane. Assessment of lipoprotein profiles study (ALPS) and antioxidant activity in healthy subjects treated with AGI-1067.
Journal of clinical lipidology.
2007 Aug; 1(4):271-9. doi:
10.1016/j.jacl.2007.07.005. [PMID: 21291691] - Claire Veryard. American Heart Association - Scientific Sessions 2006. Cell therapies for ischemic tissues and treatments for lipid metabolism disorders.
IDrugs : the investigational drugs journal.
2007 Jan; 10(1):17-9. doi:
". [PMID: 17187307] - Amy M Franks, Stephanie F Gardner. AGI-1067: a novel vascular protectant for prevention of restenosis.
The Annals of pharmacotherapy.
2006 Jan; 40(1):66-73. doi:
10.1345/aph.1g142. [PMID: 16303986] - O Cynshi, R Stocker. Inhibition of lipoprotein lipid oxidation.
Handbook of experimental pharmacology.
2005; ?(170):563-90. doi:
10.1007/3-540-27661-0_21. [PMID: 16596815] - Charles Kunsch, Jayraz Luchoomun, Janice Y Grey, Lynda K Olliff, Leigh B Saint, Richard F Arrendale, Martin A Wasserman, Uday Saxena, Russell M Medford. Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent.
The Journal of pharmacology and experimental therapeutics.
2004 Mar; 308(3):820-9. doi:
10.1124/jpet.103.059733. [PMID: 14617690] - Sheila A Doggrell. Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth.
Expert opinion on investigational drugs.
2003 Nov; 12(11):1855-9. doi:
10.1517/13543784.12.11.1855. [PMID: 14585060] - Cynthia L Sundell, Patricia K Somers, Charles Q Meng, Lee K Hoong, Ki-Ling Suen, Russell R Hill, Laura K Landers, Angela Chapman, Dustie Butteiger, Moira Jones, David Edwards, Alan Daugherty, Martin A Wasserman, R Wayne Alexander, Russell M Medford, Uday Saxena. AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent.
The Journal of pharmacology and experimental therapeutics.
2003 Jun; 305(3):1116-23. doi:
10.1124/jpet.102.048132. [PMID: 12626663] - Martin A Wasserman, Cynthia L Sundell, Charles Kunsch, David Edwards, Charles Q Meng, Russell M Medford. Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease.
The American journal of cardiology.
2003 Feb; 91(3A):34A-40A. doi:
10.1016/s0002-9149(02)03148-x. [PMID: 12645642] - Charles Q Meng, Patricia K Somers, Carolyn L Rachita, Lisa A Holt, Lee K Hoong, X Sharon Zheng, Jacob E Simpson, Russell R Hill, Lynda K Olliff, Charles Kunsch, Cynthia L Sundell, Sampath Parthasarathy, Uday Saxena, James A Sikorski, Martin A Wasserman. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis.
Bioorganic & medicinal chemistry letters.
2002 Sep; 12(18):2545-8. doi:
10.1016/s0960-894x(02)00516-4. [PMID: 12182856]